Skip to main content
Premium Trial:

Request an Annual Quote

Allegro Raises $4.5M to Support Commercialization of Lung Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Allegro Diagnostics today announced it has closed a $4.5 million Series A extension financing.

Proceeds will be used to commercialize the company's BronchoGen test in 2012. The molecular testing platform uses gene expression of normal epithelial cells in the respiratory tract for the early detection of lung cancer.

Participants in the round included existing venture investors Kodiak Venture Partners and Catalyst Health Ventures.

In a statement, Michael Webb, president and CEO of Allegro, noted that although about 300,000 bronchoscopic tests are performed yearly, the majority of results are inconclusive. As a result, patients with suspected lung cancer may not receive proper treatment.

"When used alongside standard bronchoscopy procedures, BronchoGen is intended to provide additional critical diagnostic information much earlier in the diagnostic process," Webb said.

The Maynard, Mass.-based spinout of Boston University raised $4 million in a Series A round in 2008. In late June Allegro licensed IP from BU and the University of Utah Foundation to support the BronchoGen test.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.